author-photo

Raquel Guardeño

15

Papers

135

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (25)
MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC)

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years.

2020 International Journal of Environmental Research and Public Health
Show All
- Source
- Cite
- Save
Citations (1)
Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.

2020 BMC Palliative Care
Show All
- Source
- Cite
- Save
Citations (2)
Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints

2016 Targeted Oncology
Show All
- Source
- Cite
- Save
Citations (26)
Lymphopenia and changes on peripheral blood immunophenotype in patients with hepatobiliarypancreatic tumors treated with chemoradiotherapy.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Outcome of metastases resection from gastric cancer: A Spanish multicenter retrospective study.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models

2011 International Journal of Oncology
Show All
- Source
- Cite
- Save
Citations (19)